Navigation Links
The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease
Date:11/10/2008

MONTREAL, Nov. 10 /PRNewswire/ -- Montreal Heart Institute Research Centre Director Dr. Jean-Claude Tardif presented yesterday results from a clinical trial demonstrating that VIA-2291, an investigational drug being developed by VIA Pharmaceuticals, Inc., significantly inhibited production of leukotrienes, proposed mediators of vascular inflammation, in patients with serious heart disease. VIA-2291 was well-tolerated with no serious adverse events attributed to the drug. The study was presented in a Special Session at the American Heart Association 2008 Scientific Sessions in New Orleans, Louisiana.

The study of VIA-2291 was designed to establish optimal dosing and safety data in patients with acute coronary syndromes (ACS), who recently had a heart attack or unstable angina. 191 patients were treated once daily for 12 weeks with one of three dose levels of VIA-2291 or placebo. A sub-study of patients continued for an additional 12 weeks of treatment.

Cardiologists have several therapies that help reduce heart disease risk factors, but none that specifically target inflammation, an underlying cause of atherosclerosis, which leads to major adverse cardiac events (MACE), including heart attack and stroke.

VIA-2291 is designed to be a selective and reversible inhibitor of 5-LO, a key enzyme in the biosynthesis of leukotrienes, that are important mediators of inflammation believed to be involved in the development and progression of atherosclerosis.

"VIA-2291 has the potential to be the first drug to specifically target one cardiovascular inflammatory pathway," said Dr. Jean-Claude Tardif, the VIA-2291 ACS trial's principal investigator, director of the Montreal Heart Institute Research Centre and professor of medicine at the Universite de Montreal. "These data support further clinical development of this drug, including larger outcome trials."

Study Results

The trial demonstrated a statistically significant, dose-depende
'/>"/>

SOURCE Montreal Heart Institute
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Chindex International Inc. Reports Second Quarter FY 2009 Financial Results
2. Warner Chilcott Reports Operating Results for the Quarter Ended September 30, 2008 and Updates 2008 Full Year Guidance
3. MGT Capital Investments Reports Third Quarter 2008 Financial Results and Provides Update on Recent Developments
4. China Sky One Medical, Inc. Announces Record Third Quarter 2008 Results
5. Ellex Announces Six-Month Results on Retina Regeneration Therapy
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
7. InfoLogix to Report Third Quarter Financial Results on November 10, 2008
8. Transition Therapeutics to Hold Conference Call on First Quarter Fiscal 2009 Financial Results on Monday, November 10th, at 4:30 P.M. EST
9. China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates
10. Fraxel(R) Laser Systems Shown to Provide Superior Results Compared to Pseudo Fractional Laser Technologies
11. NutraCea Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (Boston) African American women born at a low ... higher risk for developing type 2 diabetes. The findings, ... in part the higher occurrence of type 2 diabetes ... of low birth weight. , Researchers from Boston University,s ... in the Black Women,s Health Study over the course ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Not only is eating ... save them hundreds of health-care dollars a year, a new ... professor of public health sciences at Wake Forest Baptist Medical ... and obese type 2 diabetes patients. Participants ... assigned to either an intensive "lifestyle change program" focused on ...
(Date:8/21/2014)... By Dennis Thompson ... (HealthDay News) -- A combination of therapy and antidepressants ... depression, a new study reports. Four out of ... two years experienced full recovery when treated with cognitive ... other hand, the combination didn,t work much better than ...
(Date:8/21/2014)... 2014 A new study published this ... in disability associated with speech problems from 2001-02 to ... 15% increase in disability associated with hearing problems. The ... numbers of children who are experiencing communication disorders, according ... , On a broader level, the new study, ...
(Date:8/21/2014)... physicians in rural communities do not routinely screen ... Penn State medical and public health researchers. Rural ... limited resources if they seek help., "Rural health ... said Jennifer S. McCall-Hosenfeld, a primary care physician ... sciences, Penn State College of Medicine. "However, in ...
Breaking Medicine News(10 mins):Health News:Low birth weight linked to higher incidence of type 2 diabetes in African American women 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:Primary care physicians can be critical resource for abused women in rural areas 2
... guiding injured workers back to full-time employment should factor ... research suggests. , Workers who are injured on ... if their schedules routinely require them to work extended ... who work more than 12 hours per day or ...
... Supplementation tied to a 23% reduced risk of falling in ... Vitamin D2 supplements may help reduce the risk of falls ... of women older than 65 fall each year, and six ... In addition, fear of falling is a major problem in ...
... the lungs of patients diagnosed with idiopathic pulmonary ... of Cincinnati (UC) researchers have discovered. , According ... (pronounced new-tro-fil) cellsa type of white blood cellin ... increased risk of mortality in the first year ...
... and M&A activity in the,life sciences and healthcare sector ... more in 2008. CEOs, CFO,s and other business executives ... be,joined by some of the most sophisticated investors in ... Healthcare, April 30-May 1, 2008,in Chicago., Deal volume ...
... for ... Women, ST. ... causes nearly 2,400 deaths each day,in the United States, an average of ... 25 percent of the total U.S.,female population, there,s more reason than ever ...
... Enrollment Process, SAN JOSE, Calif., Jan. 16 ... 47 million uninsured in America are,eligible for government-sponsored ... Health Coverage Education (FHCE) has captured, on a,single ... people in need of health coverage., Combined ...
Cached Medicine News:Health News:Extended work hours should factor into return to job after injury 2Health News:Extended work hours should factor into return to job after injury 3Health News:Vitamin D May Curb Falls in High-Risk Older Women 2Health News:Rare lung disease cells indicate higher death risk 2Health News:Healthcare M&A Activity on the Rise 2Health News:Women May Enjoy Boost of Heart Health With Soy 2Health News:Internet Comes to Rescue of 14 Million Uninsured in U.S.; Providing Access to Gov. Health Programs They're Not Aware of 2Health News:Internet Comes to Rescue of 14 Million Uninsured in U.S.; Providing Access to Gov. Health Programs They're Not Aware of 3
(Date:8/21/2014)...   Memorial Hermann Health System and The ... a new partnership to provide a new level of specialized ... in the greater Houston area. ... exclusive provider of professional breast radiology services for five of ... The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... 2014 The spinal column is one of the ... carried to and from the brain through the column control ... Injury or ailment here can be life altering, and leave ... control over their body. Though back injury and disease can ... are more options available to make things better than ever ...
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
... Inc. (Nasdaq: NLTX ), a company focused on ... announced its second quarter financial results for 2010. ... Nile reported a net loss of approximately $1.5 million, or ... $2.5 million, or $0.10 per share, during the second quarter ...
... FRANCISCO, Calif., Aug. 16 Titan Pharmaceuticals, Inc. (OTC Bulletin ... the second quarter ended June 30, 2010. Total ... consisting primarily of grant and royalty revenues. Grant revenue from ... Phase 3 clinical study of Probuphine® was approximately $1.29 million, ...
Cached Medicine Technology:Nile Therapeutics Reports 2010 Second Quarter Financial Results 2Nile Therapeutics Reports 2010 Second Quarter Financial Results 3Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results 2Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results 3Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results 4Titan Pharmaceuticals Announces Second Quarter 2010 Financial Results 5
... of fibre bronchoscopy: The HF-compatible V series ... other fibre bronchoscopes are measured., ,The ... including the FB-19TV, FB-18V and FB-15V models ... the pediatric FB-8V, offer much better image ...
... Fujinon's therapeutic fiberoptic bronchoscopes ... operating channel with a ... large channel allows for ... passage of cytology brushes. ...
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
Large, bright images from a bronchoscope designed for routine examination and treatment....
Medicine Products: